Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants

Completed

Conditions studied: HIV Infections

In brief

The purpose of this study was to determine the washout pharmacokinetics (PK) and safety of in utero/intrapartum exposure to maternal raltegravir (RAL) in infants born to pregnant women with HIV infection who received RAL 400 mg twice daily. The study also provided data for the development of an infant RAL starting dosing regimen for IMPAACT P1110 (NCT01780831).

Key facts

Study ID
NCT01828073
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
40
Starts
2011-05-19
Expected to finish
2018-04-23
Last updated by the study team
2021-11-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.